The anti-allergic activity of *Cymbopogon citratus* is mediated via inhibition of nuclear factor kappa B (Nf-Kb) activation

Marta Santos Serafim Machado¹,³, Hugo Bernardino Ferreira Silva¹, Raimon Rios¹, Anaque Pires de Oliveira³, Noma Vilany Queiroz Carneiro¹, Ryan Santos Costa¹, William Santos Alves¹, Fabio-Luis Meneses Souza³, Eudes da Silva Velozo⁴, Silvana Alves de Souza⁵, Tania Maria Sarmento Silva⁶, Maria Lenise Silva⁶, Lain Carlos Pontes-de-Carvalho⁵, Neuza Maria Alcântara-Neves¹ and Camila Alexandrina Figueiredo¹⁎

**Abstract**

**Background:** The prevalence of allergic diseases such as asthma has significantly increased worldwide, making it a public health concern. There is an urgent need for new anti-inflammatory agents with selective pharmacology and lower toxicity. Plant extracts have been used for centuries in traditional medicine to alleviate inflammatory diseases. In this work, we evaluated the anti-allergic activity of *Cymbopogon citratus* (Cy), a medicinal herb used by folk medicine to treat asthma.

**Methods:** We used a murine model of respiratory allergy to the mite *Blomia tropicalis* (Bt) and evaluated certain parameters known to be altered in this model. A/J mice were sensitized (100 μg/animal s.c.) and challenged (10 μg/animal i.n.) with Bt mite extract and treated with 60, 120 or 180 mg/kg of Cy standardized hexane extract. The parameters evaluated included: cellular infiltrate in bronchoalveolar lavage (BAL); eosinophil peroxidase activity (EPO); histopathological examination of the lung; serum levels of specific IgE, IgG1 and IgG2a; Th2 cytokine concentrations in BAL and expression of NF-κB.

**Results:** Our results showed that oral administration of a Cy hexane extract (especially 180 mg/Kg) reduced the numbers of leukocytes/eosinophils in BAL; the eosinophil peroxidase activity in BAL; the infiltration of leukocytes in lung tissue; the production of mucus in the respiratory tract; the level of IL-4 in BAL and the nuclear expression of NF-κB.

**Conclusions:** The results presented demonstrate the potential of the Cy hexane extract to modulate allergic asthma; this extract may be an alternative future approach to treat this pathology.

**Keywords:** *Cymbopogon citratus*, Asthma, *Blomia tropicalis*, Natural products

**Background**

The prevalence of allergic diseases such as asthma has increased significantly over the past few years in developed and developing countries [1]. Dust mites are the main sources of airborne allergens, and *Blomia tropicalis* is an important sensitizing agent in tropical regions, contributing to the asthma prevalence in Brazil [2]. Allergic bronchial asthma is a complex syndrome characterized by airflow obstruction, bronchial hyper-responsiveness and airway inflammation [3] driven by T-helper type 2 (Th2) cytokines, including IL-4, IL-5 and IL-13 [4]. These cytokines promote IgE synthesis, stimulate eosinophil growth and differentiation, and increase mucus production [5]. Although the critical roles of Th2 cytokines in the pathogenesis of allergic asthma have been established, the mechanisms for over-production of Th2 cytokines in asthmatic responses are not fully understood [6]. Current guidelines for asthma treatment recommend first-line anti-inflammatory
therapy with inhaled and, in the most severe cases, systemic corticosteroids that are effective at controlling allergic airway inflammation in most cases; however, they also pose a significant risk for adverse effects, such as general or local immune suppression, diabetes, and adiposity [7]. New or complementary anti-inflammatory drugs for asthma therapy are necessary. Historically, herbal medicine has been very important in the treatment of asthma. Plant extracts and their components are known to exhibit biological activities [8]. Our research group has standardized a model of allergy using the mite *Bt* [9], obtaining therapeutic results with *Cissampelos sympodialis* and its alkaloid wariteine [10], as well as *Ocimum gratissimum* methanolic extract and rosmarinic acid [11], in the control of allergic asthma. Our objective in the present study was to investigate the immunomodulatory effects of *Cymbopogon citratus* (*Cy*) and its possible mechanisms in a murine model of allergy to *Blomia tropicalis*. The species (*Poaceae-Gramineae*), commonly known as lemongrass, is a spontaneous perennial grass that is largely distributed around the world, especially in tropical and subtropical countries [12]. Our group’s interest in investigating this plant was because it was often used as a treatment of asthma and other respiratory allergies by folk medicine in the city of Salvador, Bahia, Brazil [13]. Extracts of dried *Cy* leaves are used in traditional medicine for the treatment of inflammation, digestive disorders, diabetes, nervous disorders, and fever, as well as other health problems [14]. No report has been found referring to the anti-allergic property of this species. However, there is evidence of an anti-inflammatory property, especially the ability of the essential oils from *Cy* to inhibit iNOS and NF-κB [14]. Understanding the molecular mechanisms underlying the healing properties of natural products is crucial to finding compounds that could be useful as templates for new therapeutic drugs in the treatment of allergic diseases.

**Methods**

**Animals**

Male A/J mice (25–30 g) were used throughout the study. Animals were maintained with free access to food and water. They were obtained from the animal facilities of the Fundação Oswaldo Cruz, Bahia, Brazil. Groups of five animals were used in each experiment. All experimental procedures were approved by the Ethical Committee for Use of Experimental Animals of the Faculdade de Odontologia, Universidade Federal da Bahia, Brazil (protocol number: 02/09), and conducted according to international standards.

**Blomia tropicalis extract**

*Blomia tropicalis* mites were cultivated in a fish food-containing standardized environment, purified with saturated NaCl and lysed in a blender (51BL30; Waring Commercial, Torrington, CO, USA) in 0.15 M phosphate-buffered saline, pH 7.4 (PBS). After several centrifugations with ether (9000 × g for 10 min) to remove lipids, protein content was determined by Lowry’s method [15]; the extract was stored at −20 °C until use. *Bt* extract was standardized by determining the Blo t 5 allergen concentration using a commercial capture ELISA (INDOOR Biotechnologies, Charlottesville, VA, USA). All batches of *Bt* that were used contained 30–40 ng allergen per μg of protein.

**Preparation of hexane extract from Cymbopogon citratus**

Leaves of *Cymbopogon citratus* were obtained from Cachoeira, Bahia, Brazil and a voucher specimen was deposited in the herbarium from the Institute of Biology, Federal University of Bahia (UFBA), ALCB 98522. Preparation of the *Cy* hexane extract was performed according to the technique described by Shetty et al. (2008) in the research laboratory in the medical field (LAPEMM) of the UFBA [16]. Briefly, dry plant material was pulverized, and crude extract was prepared by a successive maceration process using hexane. After filtration, the extracts were concentrated under vacuum at 40 °C.

**HPLC-DAD-ESI-MS and CG-MS**

HPLC analysis was performed in a Shimadzu Prominence LC-20AT equipped with a SPD-M20A diode array detector (Shimadzu Corp. Kyoto, Japan). The samples were injected into a Rheodyne 7125i injector with a 20 μl loop. The column heater was set at 40 °C. The chromatographic separation was performed with a Luna Phenomenex C-18 column (250 mm x 4.6 mm x 5 μm). The compounds were separated using a mobile phase consisting of 5 % aqueous formic acid (A) and methanol (B) at a flow rate of 1 ml/min. The separation gradient was 0–20 min 50–70 % B, 20–40 min 70–90 % B, 40–50 min 90–100 % B, 50–60 min 100 % B. The injection volume was 20 μL. Chromatograms were recorded at 320 nm. The HPLC-MS was obtained in positive electrospray mode using an MS (Esquire 3000 Plus, Bruker Daltonics, Germany), capillary voltage 4500 V, nebulizer pressure 26 psi, drying gas 6.0 l/min, and gas temperature 325 °C. Gas chromatography coupled with mass spectrometry was performed using a GC-MS-QP5050 (Shimadzu Corp. Kyoto, Japan), equipped with BPX5 (5 % phenyl polysilphenylene siloxane) a capillary column (30 m x 0.25 mm i.d.,0.25 μm). For GC-MS detection, an electron ionization system was used with ionization energy of 70 eV. Helium was the carrier gas, at a flow rate of 1.7 mL/min. Injector temperature 240 °C, detector temperature 230 °C,
temperature program, temperature program: 50 °C (5 min)-250 °C, 5 °C/min. The identification of the components was made through comparison of substance mass spectrum with the database of the GC/MS (Willey229, NIST107, SHIM1607, NIST21).

The extraction of phenolics compounds from Cymbopogon citratus extract was performed using C18 cartridge. 100 mg of extract was suspended into 1 mL of MeOH and filtered and filtered to separate the precipitate. The C18 cartridge (SEP-PAK Waters) was sequentially conditioned with 10 mL of MeOH and 10 mL of acidified water (pH 2.0 with HCl) without allowing the cartridge to dry. The filtrate was passed through the cartridge and rinsed with 10 mL of water and the phenolic compounds were eluted with 10 mL of HPLC-grade methanol. The eluate was dried under Nitrogen gas furnished 18.2 mg of phenolic fraction. This fraction was dissolved in methanol, filtered through a 0.45-μm nylon syringe filter (Whatman) and injected into the HPLC system. The insoluble precipitate in methanol was solubilized with dichloromethane for GC-MS analysis.

Cytotoxicity assay
The cytotoxicity of Cy was evaluated as described by Stevignyetal (2002) using the tetrazolium salt MTT (3–4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma) colorimetric method based on the cleavage of the reagent by dehydrogenases in viable cells (Mosmann, 1983). Stock solutions of the Cy hexane extract were prepared at 10 mg/mL in DMSO. The solutions were further diluted to final concentrations of 1000–1.95 μg/mL. Cultures were incubated for 48 h at 37 °C in an atmosphere with 5 % CO2. All experiments were performed at least in duplicate.

Sensitization and challenge with Bt antigen
The murine model of respiratory allergy was induced as previously described [17]. Briefly, A/J mice (n = 5) were initially sensitized by two subcutaneous injections (day 0 and day 7) of Bt (10 μg of protein) adsorbed to 4 mg/mL Al(OH)3 in saline. 24 hours after the last subcutaneous injection, animals received three intranasal immunization boosters/challenges with Bt (10 μg instillation) every other day. Two days after the last immunization booster/challenge, they received a final intranasal challenge of 10 μg Bt. The negative control group received saline in both sensitization and challenge procedures. 24 h after the last challenge, the animals were euthanized with intraperitoneal injections of xylazine and ketamine (40 mg/kg/body weight).

Treatment with Cymbopogon citratus
The different groups were treated daily from the 8th to the 14th day of the experimental protocol, one hour after intranasal challenges on the 8th, 10th, 12th, and 14th days (Fig. 1). Animals were orally administered 60, 120 or 180 mg/kg of Cy or 3 mg/kg of dexamethasone (Dex). The groups of animals were named: Control, non-sensitized and saline-treated mice; Bt, Bt-sensitized and saline-treated mice; Bt/CcH60, Bt/CcH120 and Bt/CcH180, Bt-sensitized, Bt-challenged and Cy-treated mice; Bt/Dex, Bt-sensitized and Dex-treated mice.

Bronchoalveolar lavage (BAL)
The trachea was cannulated, and the lungs were carefully washed three times with 0.5 mL PBS containing 1 % bovine serum albumin (BSA). The total number of leukocytes in the BAL was immediately determined in a hemocytometer using Trypan blue. Differential cell counts were obtained using May–Grunwald–Giemsa-stained cytospin preparations. A differential count of at least 100 cells was performed in a blind fashion in accordance with standard morphologic criteria.

Eosinophil peroxidase (EPO) activity
EPO activity in cells obtained from BAL was measured according to a previously described method [18]. Briefly, cell suspensions were frozen and thawed three times in liquid nitrogen. After centrifugation at 4 °C for 10 min at 1000 x g, cell lysates were placed into 96-well plates (75 μL/well), followed by the addition of 150 μL of the chromogen and substrate solution (1.5 mmol/L o-phenylenediamine and 6.6 mmol/L H2O2 in 0.05 mol/L Tris–HCl, pH 8.0). After 30 min at room temperature, the reaction was stopped by the addition of 75 μL of 0.2 mol/L citric acid; the absorbance of the samples was determined at 492 nm using an ELISA reader.

Levels of IL-4 in bronchoalveolar lavage (BAL)
The concentrations of IL-4 in BAL were quantified by a standard ELISA as recommended by the manufacturer (BD Pharmingen, USA).

Measurement of anti-Bt IgE, IgG1 and IgG2a antibody levels in serum
Anti-Bt antibody levels in serum from the different experimental groups were determined by indirect ELISA: 96-well micro titer high-binding plates (Costar, Cambridge, MA, USA) were coated with Bt (100 μg/well) overnight at 4 °C and blocked for 1 h with PBS-T containing 10 % fetal calf serum (FCS, Gibco, Pisley, UK) at room temperature (RT). After this incubation period, the serum samples were added, and the plates were incubated overnight at 4 °C. Biotin-conjugated IgE, IgG1 or IgG2a anti-mouse (BD Pharmingen, San Diego, CA, USA) was added to the wells and incubated for 1 h at RT. A solution of
avidin-horseradish peroxidase (BD Pharmingen, San Diego, CA, USA) was then added to each well for 30 min. Finally, a solution containing 3,3′,5,5′-tetramethylbenzidine and hydrogen peroxide (BD Pharmingen, San Diego, CA, USA) was added and incubated for 30 min at RT; the reaction was then stopped with 4 M sulfuric acid. The absorbance of the sample was determined at 492 nm using an ELISA reader.

**Histopathological analysis**

The degree of peribronchiolar and perivascular inflammation was evaluated as described previously [19]. Briefly, lung tissues were fixed by inflation with freshly prepared 10 % (v/v) paraformaldehyde. The specimens were dehydrated and embedded in paraffin. Tissue sections (5 μm) were stained with hematoxylin and eosin to assess cellular infiltration under optical microscopy with 400× magnification. The data on quantification of lung inflammation were acquired using the software Image-Pro Plus Version 6.1 (Media Cybernetics, San Diego, CA, USA) using the inflammatory area index. Additionally, tissue sections were stained with periodic acid-Schiff to assess the presence of mucus. A quantitative digital analysis was performed as described previously [9].

**Detection of NF-κB/p65 in lung tissue by Western blot**

Lung tissue (200 mg) from each group of mice was homogenized with lysis buffer (1000 μl RIPA). The samples were centrifuged for 30 min at 200 × g and 4 °C, and the supernatant was collected. Protein concentration was determined by Lowry’s method [16]; 20 μg protein from each group was separated by 13 % SDS-PAGE (Bio Rad, Blot SD – MO – USA, 100 v 1.5 h) and electrotransferred to a nitrocellulose membrane (Hybound – ECL, Amersham Biosciences, Bio Rad, Blot SD – MO – USA, 15v 30 min). The membrane was blocked with 3 % BSA (3 g BSA was dissolved in 100 ml PBS) for 2 h at 37 °C and incubated with polyclonal rabbit anti-NF-kB (1:100) overnight at 4 °C. The membrane was washed with TBST (Tris–HCl pH7.5 5 ml, 20 % Tween-20 1.18 ml, NaCl 4.4 g, 500 ml dd Water) for 2 × 10 min, incubated with HRP labeled secondary monoclonal antibody (1:1000) for 1.0 h at 37 °C, washed with TBST 2 × 10 min and visualized using an ECL Western blot analysis system (GE Healthcare).

**Detection of NF-κB/p65 in the lung tissue by immunohistochemistry**

Lung sections (4 μm) obtained from paraffin blocks were placed on glass slides treated with poly-L-lysine (Sigma Diagnostic). The exposure of antigenic epitopes was achieved by heating (97 ° C) in citrate buffer pH 6.0 for 30 min. Endogenous blocking was performed with 3 % hydrogen peroxide in methanol for 15 min and then block was performed for nonspecific binding with 4 mg/ml bovine serum albumin (BSA) for 20 min. NF-κB/p65 antibody (Sigma) was added to tissue at a concentration of 1:80 at 4 ° C for 12 h. After washing with PBST, the sections were incubated with the secondary antibody, biotinylated IgG (Sigma 1:1000), for 1 h at room temperature. Signal amplification was performed using streptavidin-peroxidase (Pearce 1:1000). After development of the slides with DAB 3,3′ diaminobenzidine (DAB, Dako, Carpinteria, USA), the slides were counter-stained with hematoxylin and mounted with glass coverslips containing Canada balsam (Riedel de Haen AG, Hannover, Germany). The data on quantification of NF-κB expression were acquired using the software Image-Pro Plus Version 6.1 (Media Cybernetics, San Diego, CA, USA) using the expression area index.
Fig. 2 Chromatogram obtained by gas chromatography coupled with mass spectroscopy

Fig. 3 HPLC-DAD (320 nm) chromatogram of phenolic fraction of Cy and UV of representative compounds 1, 4, 7, 8, 13 and 15
Statistical analysis
One-way analysis of variance (ANOVA) and Tukey’s post-test (for data with normal distribution) were used to determine the significance between experimental groups. Differences with \( p \) values \( \leq 0.05 \) were considered statistically significant. Each experiment was repeated at least two times.

Results

Standardization hexane extract from *Cymbopogon citratus*
The chromatogram obtained by gas chromatography coupled with mass spectrometry is presented in Fig. 2. The analysis showed the main compounds: 2-hydroxy-4-methyl2-pentanone (3.89 %), elemol (2.53 %), beta esdesmol (2.30 %), oplapanone (4.79 %), nerolidol epox-yacetate (2.78 %), phytol acetate (5.66 %), eicosanoic acid methyl ester (1.89 %), palmitic acid (8.49 %) and phytol (1.82). The phenolic composition of *Cy* extract was investigated using a HPLC method with diode array and mass spectrometric detection. 15 compounds tentative peak assignment partly were assigned as sinapic acid derivatives with the exception of substances four and five which can be derived from ferulic acid. The compounds derivatives of sinapic acid may be characterized as sinapate esters. The major fragments were found at \( m/z \) 221, 203 and 147. The fragments to esters of ferulic acid were observed at \( m/z \) 195, 155 and 137. The UV spectra (Figs. 3 and 4) corroborate the proposal for derivatives of cinnamic acids because the maximum lambda values observed between 290 and 338 nm nm [20].

*Cymbopogon citratus* has no significant cytotoxicity in spleen cells from mice
Our results show that cultures treated with different concentrations of *Cy* not had significant differences of dead cells, when compared to the negative control. Thus, *Cy* has no cytotoxicity at the concentrations evaluated (Fig. 5).

![Figure 4](image1.png)

**Fig. 4** TIC chromatogram of phenolic fraction of *Cy* from HPLC (+) ESI-MS

![Figure 5](image2.png)

**Fig. 5** Evaluation of the cytotoxicity of *Cymbopogon citratus* hexane extract on cultured splenocytes of mice sensitized with Bt antigen. Effect of hexane extract of *Cymbopogon citratus* (*Cy*H) on spleen cells. Cells were exposed to supplemented RPMI medium (Control) or supplemented RPMI medium and various concentrations of *Cy*H (1000 at 1.95 \( \mu \)g/ml) by 48 h at 37 °C in an atmosphere with 5 % \( \text{CO}_2 \). The MTT assay was performed as described in Materials and Methods.
Treatment with *Cymbopogon citratus* hexane extract decreases the number of inflammatory cells and eosinophil peroxidase (EPO) levels in mice sensitized with *Bt* antigen

As shown in Fig. 6, an increase in total leukocytes and eosinophils in BAL of *Bt*-sensitized animals was observed when compared to the negative control group (*p* < 0.001; Fig. 6a). Among the groups treated with *Cy* extract, daily oral administration of 60, 120 or 180 mg/kg resulted in a significant reduction in the number of inflammatory cells and eosinophils (*p* < 0.001; Fig. 6b) when compared to *Bt*-sensitized animals. Animals sensitized with *Bt* had higher EPO activity in lung tissue (*p* < 0.001; Fig. 6c) compared to the control group. Mice treated with *Cy* hexane extract showed a significant reduction in EPO levels in the BAL at all administered doses (*p* < 0.001; Fig. 6c). As expected, the oral administration of 3 mg/kg Dex significantly suppressed the number of eosinophils, total inflammatory cells and EPO levels (*p* < 0.001; Fig. 6c).

![Fig. 6](image-url)
Treatment with *Cymbopogon citratus* hexane extract decreases the levels of *Bt*-specific IgE, IgG1 and IgG2a in the serum of mice sensitized with *Bt* antigen

Figure 7 presents the levels of anti-IgE, IgG1 and IgG2a specific for *Bt* in sensitized and treated animals. As shown in this figure, mite sensitization induced high levels of these antibodies when compared to the control group (*p* < 0.001; Fig. 7a-c). Treatment with 180 mg/kg of *Cy* significantly reduced the level of IgE (*p* < 0.01; Fig. 7a). The oral administration of 3 mg/kg Dex significantly reduced the level of IgE (*p* < 0.01; Fig. 7a).

Daily oral administration of 120 mg/kg (*p* < 0.05; Fig. 3b) or 180 (*p* < 0.01; Fig. 7b) reduced the levels of IgG1 in the serum of *Bt*-sensitized mice. Treatment with 3 mg/kg Dex decreased levels of IgG1 (*p* < 0.001; Fig. 7b) in *Bt*-immunized and challenged mice. Treatment with *Cy* did not significantly reduce IgG2a serum immunoglobulins levels (Fig. 7c).

Treatment with *Cymbopogon citratus* hexane extract decreases IL-4 levels in the BAL of *Bt*-sensitized mice

Levels of IL-4 in the BAL were higher in *Bt*-immunized and challenged mice compared to the control group.

![Figure 7](image-url)
Treatment with *Cymbopogon citratus* hexane extract decreases inflammatory cell infiltration in lung tissue of mice sensitized with *Bt* antigen

Figure 9b shows a cellular infiltrate that is characteristic of allergic asthma, including leukocyte infiltration around the bronchioles and perivascular region. Oral treatment with 60, 120 and 180 mg/kg Cy reduced inflammatory cell infiltration around the bronchioles (*p* < 0.05, Fig. 9c; *p* < 0.01, Fig. 9d and *p* < 0.001, Fig. 9e). As expected, treatment with 3 mg/kg Dex decreased inflammation in the lung tissue of Bt-immunized and challenged mice (*p* < 0.001, Fig. 9f). The reduction of inflammation was confirmed by quantification of inflammatory area.

Treatment with *Cymbopogon citratus* hexane extract decreases mucus production in lungs of *Bt*-immunized animals

In our experimental model of allergic asthma induced by mite *Blomia tropicalis*, intense mucus production can be observed in the lung tissue of Bt-sensitized and challenged animals (*p* < 0.001, Fig. 10b). In contrast, treatment with 60, 120 and 180 mg/kg hexane extract reduced mucus production (*p* < 0.05, Fig. 10c; *p* < 0.01, Fig. 10d–e). As expected, treatment with 3 mg/kg Dex decreased production of mucus in lung tissue of Bt-immunized and challenged mice (*p* < 0.001, Fig. 10f). The reduction of mucus production was further confirmed by quantification analysis as shown in Fig. 10g.

**Discussion**

*Cymbopogon citratus* is commonly used in folk medicine to treat nervous and gastrointestinal disturbances and as an antispasmodic, analgesic, anti-inflammatory, antipyretic, diuretic and sedative [21]. Studies on the
extracts from Cy leaves have demonstrated antioxidant, anti-microbial and anti-fungal activities [22]. The chromatogram obtained by gas chromatography coupled with mass spectrometry showed the main compounds with different profile for nonpolar substances from Cy extract may be attributed to the extraction method. Of the substances identified some have been previously observed in aqueous extract of Cy, such as β-eudesmol, that has anti-inflammatory activity by suppression of the NF-κB-expression [22, 23]. However, no previous study has explored the anti-allergic potential of Cy.

We have previously demonstrated the ability of natural products to modulate inflammatory cell recruitment to lung tissue [10]. Eosinophilia, eosinophil migration to the lungs, and their secreted products, such as inflammatory cytokines, are important factors that determine the severity and exacerbation of allergic diseases [18]. The present study was performed using a murine model of allergic disease induced by a common aeroallergen described by our group [9]. This work showed that treatment with Cymbopogon citratus reduced the infiltration of total leukocytes, particularly eosinophils, mucus production, and NF-κB expression in the lung tissue of Bt-sensitized animals. Treatment with the extract also reduced the production of eosinophil peroxidase, and suppressed levels of IgE, IgG1 and IL-4. Our results show that Cy suppressed EPO activity at all tested doses in Bt-sensitized animals. These data are related to the reduction in the number of eosinophils in the BAL of animals treated with Cymbopogon citratus, highlighting the important role of Cy extract in reducing inflammation and remodeling of lung tissue in allergic asthma.

An emerging concept asserts that the nature and intensity of granulocytic infiltration of the airways, in
particular the presence or absence of increased numbers of eosinophils, defines disease pathophysologically and clinically [24].

The majority of asthma cases are associated with Th2-type T-lymphocyte–driven cell recruitment and mediator release involving mast cells, eosinophils, basophils, and macrophages that contribute to chronic, sub acute, and acute inflammatory responses [25]. Inflammatory cytokines such as IL-4, IL-5 and IL-13 are induced in the lung during asthma exacerbations [25]. To evaluate the mechanism of the Cy-mediated modulation of eosinophil infiltration, we investigated the effect of Cymbopogon citratus on the production of the Th2-type cytokine IL-4. Inhibition of inflammation is an essential process to establish homeostasis. We observed reduced levels of IL-4 after oral administration of 60 mg/kg, 120 mg/kg and 180 mg/kg Cy extract when compared to Bt-sensitized and treated with saline animals.

An important, consistent feature of asthma is the production of excess, altered mucus that blocks peripheral airways [25]. In asthma, there is ample evidence for goblet cell metaplasia involving the conducting airways; IL-4 and IL-13 also induce the production of TGF-β by epithelial cells that, through autocrine signaling, results in the mucus metaplasia that is characteristic of Th2-mediated inflammation [24]. Animals treated with the Cy hexane extract showed reduced mucus production in lung tissue, at all doses administered, stained with PAS.
These results suggest decreased hyperplasia and hypersecretion of goblet cells in the airways obstruction a common feature in asthma pathology.

Our results showed that treatment with 180 mg/kg Cy extract decreased the levels of Bt-specific IgE in Bt-immunized mice; the levels of IgG1 were decreased when mice were treated with 120, 180 mg/kg Cy extract. Production of IgE depends on Th2-type cytokines, such as IL-4 [26]. Down-modulation of IgE production, as well as the reduction of IL-4, constitutes an important strategy for treating allergic diseases because the treatment of allergic asthma patients with IgE antibody was confirmed to attenuate eosinophilic airway inflammation [27] may have an important anti-allergic effect.

**Fig. 11** Detection of NF-κB expression in lung tissue of mice sensitized with Bt antigen. A/J mice were sensitized and treated with saline (Control), sensitized with Blomia tropicalis (100 μg/animal) and 4 mg/mL of [AL(OH)₃] and treated with saline (Br) or sensitized with Blomia tropicalis (100 μg/animal) and 4 mg/mL of [AL(OH)₃] and treated with Cymbopogon citratus (Cy) hexane extract at 120 mg/kg (Br/CyH120) or 3 mg/kg dexamethasone (Br/Dex). Each lane is representative of the results obtained from five animals.

**Fig. 12** Effect of Cymbopogon citratus treatment on expression of NF-κB p65 in the lung tissue of mice sensitized with Bt antigen. Sections were stained by immunohistochemistry (magnification × 400). Lung sections from A/J mice sensitized and treated with saline a, sensitized with Blomia tropicalis (100 μg/animal) and 4 mg/mL of [AL(OH)₃] and treated with saline b, sensitized with Blomia tropicalis (100 μg/animal) and 4 mg/mL of [AL(OH)₃] and treated with Cymbopogon citratus (Cy) hexane extract at 120 mg/kg c, 120 mg/kg d, 180 mg/kg e or 3 mg/kg dexamethasone f. g presents the quantification of NF-κB p65 expression, Scale bar, 100 μm.
The molecular mechanisms underlying the protective effects of Cymbopogon citratus in allergic asthma are not fully established. However, Edwards and colleagues (2009) found that the anti-inflammatory effects of Cymbopogon citratus may be due to suppression of NF-κB activation [28]. One of the molecular mechanisms related to the effect of glucocorticoids is the inhibition of transcription factors such as NF-κB that are related to the production of inflammatory cytokines [29].

NF-κB exists in the cytoplasm in a latent form as a complex consisting of a dimer of DNA-binding subunits bound to an inhibitor, IκB. Activating agents, such as cytokines or lipopolysaccharide (LPS), induce the degradation of cytosolic IκB, promoting the release and nuclear translocation of NF-κB dimers. In most cells, the NF-κB is a heterodimer composed of the p65 and p50 subunits. This variant is the most potent gene transactivator among the NF-κB family and is the major NF-κB protein found in the nucleus of cytokine-stimulated cells. The transcription factor NF-κB is a central regulator of the transcriptional activation of a number of genes involved in proinflammatory responses [30].

Lee and colleagues (2008) found that Citral, a of the major compound of Cymbopogon citratus inhibited iNOS expression, NO production and various LPS-induced pathways, including p38 mitogen-activated protein kinase (MAPK), c-jun NH2-terminal kinase (JNK) 1/2 and the transcription factor NF-κB [14]. In this work, we showed that treatment with our Cymbopogon citratus extract at all administered doses of 60 mg/kg decreased NF-κB/p65 expression in the lung tissue of Blomia tropicalis-sensitized animals, as determined by immunohistochemistry (Fig. 12). We also showed that treatment with Cymbopogon citratus at a dose of 120 mg/kg decreased NF-κB nuclear expression in lung tissue when compared to control groups of Blomia tropicalis-sensitized mice or mice sensitized with saline (Fig. 11). This may be one of the probable mechanisms mediating the anti-inflammatory effect of Cymbopogon citratus. These findings are consistent with and corroborated by Francisco and collaborators (2011) which evidences the potential of Cymbopogon citratus as a source of compounds with anti-inflammatory properties, as well as the expression of NF-κB [21]. The data suggest that Cymbopogon citratus is a potential herb that can be used to control allergic asthma, reducing extensive infiltration of inflammatory cells into the lungs while also potentially inhibiting NF-κB expression in the lung. Further studies are needed to verify the mechanism of action of Cymbopogon citratus extract, to identify the possible active compounds within the extract responsible for the properties observed and the mechanism whereby it occurs.

Conclusion
The results presented in this study demonstrate the anti-allergic activity of Cymbopogon citratus extract in an experimental murine model of allergic asthma. Additional studies are being conducted in our group to describe possible mechanisms involved in allergic disease control by using Cymbopogon citratus as well as, isolated Cymbopogon citratus compounds.

Abbreviations
BAL: Bronchoalveolar lavage; BSA: Bovine serum albumin; Bt: Blomia tropicalis; ECL: Enhanced chemiluminescence; ELISA: Enzyme immunoassay test; EPO: Eosinophil peroxidase; HBSS: Hanks’ balanced salt solution; HCl: Hydrochloric acid; IL: Interleukin; IL-4: Interleukin 4; IL-5: Interleukin 5; IL-13: Interleukin 13; IFN-γ: Interferon gamma; i.n.: Intranasal; IgE: Immunoglobulin E-type; LPS: Lipopolysaccharide; NaCl: Sodium chloride; NaOH: Sodium hydroxide; NF-κB: Nuclear factor-κB; OVA: Ovalbumin; OD: Optical density; PAS: Periodic acid Schiff; PBS: Phosphate-buffered saline; PBST: Phosphate-buffered saline containing 0.05% Tween; PWM: Pokeweed mitogen; RPM: Revolutions per minute; s.c.: Subcutaneous; Th1: T helper lymphocyte type 1; Th2: T helper lymphocyte type 2; Treg: Regulatory T lymphocytes; v.o.: Oral; RIPA: Lysis buffer system; iNOS: Inducible nitric oxide synthase.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
MMSS significantly contributed to performed the present study, wrote the manuscript and conducted the laboratory assays. SHB, RR, AO and CRS helped in the study design, conducted the laboratory assays and manuscript revision. QNV and WAS helped the laboratory assays. FLM and VES contributed to the collection of Cymbopogon citratus and production of extract. SSA and STMS contributed technical chromatographic and spectrometry. PCLC and ANNM contributed technical support for the development of this work. FCA conceived the work, the study design, supervised the immunological assays and manuscript revision. TMSS and SAS contributed to the standardization of the Cymbopogon citratus extract. All authors read and approved the final manuscript.

Acknowledgments
The authors wish to thank the Brazilian agencies FAPESB, FACEPE, CNPq and CAPES for financial support.

Author details
1Departamento de Bioregulação, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Campus do Canela, CEP 41110-100 Salvador, BA, Brazil. 2Centro de pesquisa Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil. 3Faculdade Adventista da Bahia, Cachoeira, Bahia, Brazil. 4Faculdade de Farmácia da Universidade Federal da Bahia, Salvador, Bahia, Brazil. 5Departamento de Ciências Moleculares, Laboratório de Bioprospecção Fitoquímica da Universidade Federal Rural de Pernambuco, 52171-900 Recife, Pernambuco, Brazil. 6Instituto de Biologia, Universidade Federal da Bahia, Salvador, Bahia, Brazil.

Received: 8 February 2014 Accepted: 29 May 2015
Published online: 06 June 2015
can occur independently of IL-4 and allergen-specific immunoglobulins. J Clin Invest. 1997;99:1329–39.

7. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, Fitzgerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143–78.

8. Içcan C, Krimmer N, Kucukcigil M, Bager KH, Demirci F. Antimicrobial screening of Mentha piperita essential oils. J Agric Food Chem. 2002;50:943–6.

9. Baqueiro T, Russo M, Silva VM, Meirelles T, Oliveira PR, Gomes E, et al. Respiratory allergy to Blomia tropicalis: immune response in four syngeneic mouse strains and assessment of a low allergen-dose, short-term experimental model. Respi Res. 2010;11:51.

10. Cerqueira-Lima AT, Alcântara-Neves NM, de Carvalho LC, Costa RS, Barbosa-Filho JM, Piuvezam M, et al. Effects of Cissampelos sympodiialis Eichl. and its alkaloid, warifteine, in an experimental model of respiratory allergy to Blomia tropicalis. Curr Drug Targets. 2010;11:1458–67.

11. Costa RS, Cameiro TC, Cerqueira-Lima AT, Queiroz NV, Alcântara-Neves NM, Pontes-de-Carvalho LC, et al. Ocimum gratissimum Linn. and rosmarinic acid, attenuate eosinophilic airway inflammation in an experimental model of respiratory allergy to Blomia tropicalis. Int Immunopharmacol. 2012;13:126–34.

12. Negrelle RRB, Gomes EC. Cymbopogon citratus (DC) Stapf: chemical composition and biological activities. vol. 9. pp. 80–92, Revista Brasileira de Plantas Medicinais. 2007. p. 80–92.

13. Costa R, Brasil T, Santos C, Santos D, Barreto M, Alcântara-Neves N, et al. Avaliação do uso de remédios caseiros para tratamento de asma em crianças residentes no município de Salvador-BA-Brasil, vol. 20. pp. 594–599. Curitiba: Revista Brasileira de Farmacognosia; 2010. p. 594–9.

14. Lee HJ, Jeong HS, Kim DJ, Noh YH, Yuk DY, Hong JT. Inhibitory effect of citral on NO production by suppression of iNOS expression and NF-kappa B activation in RAW264.7 cells. Arch Pharm Res. 2008;31:342–9.

15. Lowery OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–75.

16. Shetty S, Udupa S, Udupa L. Evaluation of antioxidant and wound healing effects of alcoholic and aqueous extract of Ocimum sanctum Linn in rats. Evid Based Complement Alternat Med. 2008;595–101.

17. Elias JA, Kang MJ, Crothers K, Crouthers K, Homer R, Lee CG. State of the art. Mechanistic heterogeneity in chronic obstructive pulmonary disease: insights from transgenic mice. Proc Am Thorac Soc. 2006;3:494–8.

18. Fujimoto K, Kubo K, Matsuzawa Y, Sekiguchi M. Eosinophil cationic protein levels in induced sputum correlate with the severity of bronchial asthma. Chest. 1997;112:1241–7.

19. Takano H, Onakabe N, Sanbongi C, Yanagisawa R, Inoue K, Yasuda A, et al. Activation of Perilla frutescens enriched for rosmarinic acid, a polyphenolic phytochemical, inhibits seasonal allergic rhinoconjunctivitis in humans. Exp Biol Med (Maywood). 2004;229:247–54.

20. Engel C, Schieber A, Gänzle M. Sinapic acid derivatives in defatted Oriental mustard (Brassica juncea L.) seed meal extracts using UHPLC-DAD-ESI-MSn and identification of compounds with antibacterial activity, pp. 535–542. 2012. p. 535–42.

21. Francisco V, Figueirinha A, Neves BM, Garcia-Rodriguez C, Lopes MC, Cruz MT, et al. Cymbopogon citratus as source of new and safe anti-inflammatory drugs: bio-guided assay using lipopolysaccharide-stimulated macrophages. J Ethnopharmacol. 2011;133:818–27.

22. Halabi MF, Sheikh BY. Anti-proliferative effect and phytochemical analysis of Cymbopogon citratus extract. Biomed Res Int. 2014;2014:906239.

23. Seo MJ, Kim SJ, Kang TH, Rim HK, Jeong HJ, Um JY, et al. The regulatory mechanism of β-eudesmol is through the suppression of caspase-1 activation in mast cell-mediated inflammatory response. Immunopharmacol Immunotoxicol. 2011;33:178–85.

24. Humbert M, Durham SR, Kimmitt P, Powell N, Assoufi B, Pfister R, et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol. 1997;99:657–65.

25. Galli SJ, Tsai M, Piliopinsky AM. The development of allergic inflammation. Nature. 2008;454:445–54.

26. Cory DB, Khedrmand F. Induction and regulation of the IgE response. Nature. 1999;402:818–23.

27. Holgate S, Smith N, Massanari M, Jimenez P. Effects of olanzapine on markers of inflammation in patients with allergic asthma. Allergy. 2009;64:1728–36.

28. Edwards MR, Bartlett NW, Clarke D, Birell M, Belvisi M, Johnston SL. Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther. 2009;121:1–15.

29. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373:1905–17.

30. Ruben SM, Narayanam R, Klement JF, Chen CH, Rosen CA. Functional characterization of the NF-κB p65 transcriptional activator and an alternatively spliced derivative. Mol Cell Biol. 1992;12:444–54.